CHRONIC INFLAMMATION OF THE gastric mucosa is a serious public health problem worldwide. Risk factors associated with chronic gastritis include smoking, aspirin use, and heavy alcohol consumption, but the principal association of gastritis is with stomach infection by Helicobacter pylori (38, 41, 57) . More than half of the world's population is infected with H. pylori, which is strongly linked to the development of duodenal and gastric ulcers and stomach cancer. However, the vast majority (Ͼ80%) of infected individuals are asymptomatic beyond histologic inflammation. For example, from an estimated 50 -100 million individuals in the U.S. currently infected with H. pylori, only about 25,000 new cases of stomach cancer are diagnosed each year (3) . Given the high prevalence of H. pylori in the human population, it is enigmatic why only a subset of infected individuals develops gastric disease.
Among the theories that have been promulgated, the Correa hypothesis proposes that chronic and persistent gastritis during a lifetime of H. pylori infection creates a selfperpetuating, auto-amplifying, proinflammatory environment promoting carcinogenesis (12) . In support of this hypothesis, chronic stomach inflammation in H. pylori-infected individuals is directly correlated with gastric morphological changes, failure of apoptosis, and the presence of precancerous lesions and tumors (36) .
As with most epithelia, the gastric innate immune response is primarily initiated by the pattern recognition receptors, including Toll-like receptors (TLRs) and Nod-like receptors (47) . Pattern recognition receptors recognize pathogen-associated molecular patterns, leading to the activation transcription factors [NF-B, activator protein 1 (AP-1), cAMP response element binding 1 (CREB-1)] that induce the production of proinflammatory cytokines (e.g., TNF-␣) and chemokines (e.g., IL-8). These inflammatory mediators are responsible for the recruitment and activation of immune effector cells, resulting in pathogen clearance through phagocytosis, production of antimicrobial peptides, and release of reactive oxygen species. Normally, following successful eradication of the colonizing pathogen, mucosal anti-inflammatory responses are elicited to counterregulate the comparatively nonspecific effector mechanisms of innate inflammation. Left unchecked, however, uncontrolled inflammation can lead to host bystander tissue damage and disease.
While much is known concerning the proinflammatory pathways that are activated following microbial colonization of epithelial surfaces, relatively few studies have characterized the counterbalancing, anti-inflammatory responses. In the gastric mucosa, IL-10, TGF-␤, and peroxisome proliferator-associated receptor-␥ (PPAR␥) have been identified as anti-inflammatory mediators (49, 52) . Our published studies using an H. pylori mouse infection model system demonstrated that MUC1, a membrane-tethered mucin glycoprotein, also downregulates inflammatory responses in gastric epithelial cells (18) . Other investigators reported that MUC1 expression not only limits H. pylori colonization of the murine gastric mucosa, but also attenuates the associated gastritis (39) . Together, these studies confirmed by H. pylori stomach infection what had previously been reported in a Pseudomonas aeruginosa mouse airway infection model (35) . In particular, in vivo and in vitro mechanistic studies during P. aeruginosa lung infection revealed that an initial increase in TNF-␣ levels early during the course of infection upregulated MUC1 protein expression which, in turn, suppressed later TLR signaling and inflammation subsequent to clearance of the bacteria (25, 53) . Given that PPAR␥ inhibits gastric inflammatory responses to H. pylori (49) , it is interesting to note that the Muc1 gene promoter contains a predicted PPAR␥ binding site, and that activation of PPAR␥ increased MUC1 mRNA levels in a mouse trophoblast cell line (48) . Therefore, in the present study we investigated the functional relationship between MUC1 and PPAR␥ in the inflammatory response of gastric epithelial cells.
MATERIALS AND METHODS
Cells. AGS (cat. no. CRL-1739; ATCC, Manassas, VA) and NCI-N87 (cat. no. CRL-5822, ATCC) human gastric epithelial cells were cultured in DMEM/F-12 medium containing 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin (Invitrogen, Carlsbad, CA). The cells were washed with PBS and treated for 24 h with 1.0 M phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO), H. pylori at a multiplicity of infection (MOI) of 100 or with DMSO or PBS vehicle controls. In some experiments, the cells were pretreated for 24 h with 0.1 or 1.0 M troglitazone (TGN) or DMSO control. These concentrations of TGN were chosen based on our prior dose-response experiments (42) . Viability of the treated AGS cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN). Optical densities at 492 nm and 630 nm were measured and corrected for background absorbance using MTT plus culture medium alone.
Bacteria. H. pylori strain 26695 (51) was maintained on Columbia blood agar containing 7% defibrinated horse blood (Cleveland Scientific, Bath, OH), 20 g/ml bacitracin, 20 g/ml trimethoprim, 16 g/ml cefsulodin, 6.0 g/ml vancomycin, and 2.5 g/ml fungizone (Sigma) under microaerophilic conditions as described (14) . For treatment of AGS cells, bacteria were grown in static liquid cultures of Brucella broth (Difco, Detroit, MI) containing 10% heat inactivated FBS and antibiotics at 37°C with 10% CO 2. Bacteria were washed two times with PBS, resuspended in DMEM/F-12 medium containing 10% FBS, and incubated with the AGS cell cultures without antibiotics.
IL-8 ELISA. IL-8 was quantified by ELISA using commercially available capture and detection antibodies (R&D Systems, Minneapolis, MN) as described (18, 25) . Briefly, microwells containing capture antibody, were blocked with PBS containing 1.0% BSA, AGS cell culture media were added and incubated for 2 h at room temperature, followed by sequential incubations with biotinylated detection antibody, peroxidase-labeled streptavidin, and tetramethylbenzidine substrate. Optical density values at 450 nm were measured, and IL-8 levels were determined from standard curves constructed with serial dilutions of purified chemokine on each plate.
Knockdown of MUC1 expression by small interfering RNA. AGS cells in 24-well plates were transfected with 20 pmoles/well of a MUC1-targeting small interfering RNA (siRNA) (sense, 5=-GUUCAGUGCCCAGCUCUACdTdT-3=; antisense, 5=-GUAGAGCUGGGCACUGAACdTdT-3=) or with a nontargeting control siRNA (sense, 5=-GCGCGCUUUGUAGGAUUCGdTdT-3=; antisense, 5=-CGAAUCCUACAAAGCGCGCdTdT-3=) (Dharmacon, Lafayette, CO), using 2.0 l/well of Lipofectamine (Invitrogen) as described (18) . Prior studies have documented the specificity of the MUC1 siRNA with no demonstrable off-target effects (18, 23, 30, 32, 33, 35) .
Western blot analysis. AGS cells in 60-mm dishes were washed with PBS and lysed at 4°C with PBS, pH 7.2, 1.0% Nonidet P-40, 1.0% sodium deoxycholate, and 1.0% protease inhibitor cocktail (Sigma) as described (18) . Equal protein aliquots (30 g) were resolved on 15% SDS-polyacrylamide gels, transferred to PVDF membrane (Bio-Rad, Richmond, CA), the membrane was blocked for 1 h with PBS containing 0.05% Tween 20 (PBS-T) and 5% nonfat dry milk (Sigma), and reacted with monoclonal antibodies against MUC1 (CT2) or PPAR␥ (H-100) (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:1,000. Membranes were washed with PBS-T, incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:5,000 and developed with enhanced chemiluminescence substrate (Thermo Scientific, Rockford, IL). To confirm equivalent protein loading and transfer, the blots were stripped with 62.5 mM Tris·HCl, pH 6.7, 100 mM 2-mercaptoethanol, and 2.0% SDS reblocked, and probed with monoclonal antibody against ␤-tubulin (Santa Cruz Biotechnology) followed by secondary antibody and chemiluminescence substrate. Immunoreactive bands were identified by comigration of prestained protein size markers (Bio-Rad).
H. pylori stomach infection and histopathology. An in vivo H. pylori gastric infection model system has been previously described (13, 14, 17, 18) . In this system, colonization efficiency is routinely Ͼ90% as determined by the percent of infected animals from which H. pylori can be recovered, either as viable bacteria and by testing for bacterial urease, oxidase, and catalase activities to confirm their identity as H. pylori, or by real-time RT-PCR for bacterial gene sequences (e.g., urease C). Colonization efficiency positively correlates with gastric histology. Briefly, mice were infected by gastric intubation on two consecutive days with 0.5 ml of log phase cultures of H. pylori strain SS1 (14) at 1.0 ϫ 10 7 colony forming units/animal as described (18) . Mice were killed by intraperitoneal pentobarbital injection at 4 wk postinfection, the time of maximal neutrophil infiltration of the gastric mucosa using our in vivo infection model system (14) . Stomach strips were fixed in K-2 fixative (2.0% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M sodium cacodylate buffer, 0.025% CaCl 2), and the fixative was replaced with 0.1 M sodium cacodylate buffer (4°C) containing sodium azide (pH 7.35 to 7.40) (14) . Tissues were paraffin embedded and sectioned for analysis by Giemsa staining. Neutrophils in the submucosa and gastric mucosa were enumerated per high-power field by a pathologist certified in anatomic pathology. All protocols were approved by the University of Maryland Baltimore Institutional Animal Care and Use Committee.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) analysis was performed as we previously described (25) . Briefly, following treatment with 1.0 M TGN or DMSO, AGS cells were treated with 1% formaldehyde for 10 min at 37°C to cross-link DNA-protein complexes. Formaldehyde was inactivated with 0.125 M glycine for 5 min, the fixed cells were washed with ice-cold PBS, lysed with 200 l of 50 mM Tris·HCl, pH 8.1, 1% SDS, 10 mM EDTA, and 1.0% protease inhibitor cocktail, and the cell lysates were sonicated to shear DNA to an average size of 500 bp. The lysate was centrifuged at 14,000 rpm, the supernatant was diluted 10-fold with 16.7 mM Tris·HCl, pH 8.1, 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 150 mM NaCl, and 1.0% protease inhibitor cocktail, and an aliquot of the diluted sample was kept at 4°C after adjusting the NaCl concentration to 200 mM as the input sample. The remaining sample was immunoprecipitated overnight at 4°C with PPAR␥ antibody (Santa Cruz Biotechnology), followed by incubation for 1 h at 4°C with protein A agarose. After centrifugation, the resulting agarose pellet was sequentially washed once with 20 mM Tris·HCl, pH 8.1, 0.1% SDS, 1.0% Triton X-100, 2.0 mM EDTA, and 150 mM NaCl; once with 20 mM Tris·HCl, pH 8.1, 0.1% SDS, 1.0% Triton X-100, 2.0 mM EDTA, and 500 mM NaCl; once with 10 mM Tris·HCl, pH 8.1, 1.0% NP-40, 1.0% deoxycholate, 1.0 mM EDTA, and 0.25 M LiCl; and twice with 10 mM Tris·HCl, pH 8.0 and 1.0 mM EDTA. The agarose pellet was incubated for 15 min at room temperature with 1.0% SDS, 0.1 M NaHCO3, and 10 mM DTT, and the protein-DNA cross-linkages were reversed for 6 h at 65°C with 200 mM NaCl after proteinase K treatment. DNA was extracted with phenol-chloroform, precipitated with ethanol, and subjected to PCR with 40 cycles of amplification as we described (25) to generate a 320 bp amplicon using the Muc1 forward primer 5=-GGCTGCTTGAGAGGTGGGGCACA-3= and the reverse primer 5=-GTTGCCCTGAGGCTAAAACTAGAG-3=. PCR products were visualized on ethidium bromide-stained agarose gels, quantified by densitometry, and normalized to input signal.
Luciferase assays. AGS cells in 24-well plates were incubated for 24 h, the medium was replaced with DMEM/F-12 containing 0.1% FBS, and the cells were incubated for an additional 24 h. The cells were cotransfected with 80 ng/well of a Muc1 promoter-firefly luciferase reporter plasmid (Muc1-pGL2b), an IL-8 promoter-lucifease reporter plasmid (IL-8-pGL2b), or with the empty pGL2 vector, plus 10 ng/well of the phRL-TK internal control plasmid encoding Renilla luciferase (Promega, Madison, WI) using Lipofectamine (Invitrogen) as we described (18, 28) . Luciferase activities were measured in cell lysates using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Luciferase activity driven by the Muc1 promoter was normalized to the internal control by calculating the ratio of firefly luciferase activity to Renilla luciferase activity of each sample.
Statistical analysis. Replicates of 3-4 samples were used for each group and mean Ϯ SE values were calculated. Differences between means were assessed using Student's t-test and were considered significant at P Ͻ 0.05.
RESULTS

PMA stimulates IL-8 production by gastric epithelial cells through a MUC1-dependent mechanism.
Our previous study demonstrated that MUC1 expression blocked H. pylori-stimulated IL-8 production in AGS cells at the level of the IKK/ NF-B complex (18) . These results were entirely consistent with published reports demonstrating that MUC1 inhibited P. aeruginosa-induced, TLR-dependent proinflammatory responses by human and mouse airway epithelial cells (22, 35, 53) . Because a variety of different agonists and receptors stimulate proinflammatory responses through NF-B, in the present study we evaluated IL-8 production by AGS cells in response to a TLR-dependent (H. pylori) (16) and a TLRindependent (PMA) (9, 20) NF-B-activator. Treatment of AGS cells for 24 h with 1.0 M PMA increased IL-8 levels in cell culture supernatants compared with cells treated with DMSO vehicle alone (Fig. 1A) . Prior knockdown of MUC1 expression by transfection of the cells with a MUC1-targeting siRNA further increased PMA-induced IL-8 levels compared with cells transfected with a nontargeting control siRNA (Fig.  1B) . Western blot analysis verified Ͼ 90% MUC1 silencing in MUC1 siRNA-transfected AGS cells (Fig. 1C) .
TGN inhibits PMA-stimulated IL-8 production. PPAR␥ plays an important regulatory role in gastric inflammatory responses and the development of stomach cancer (26, 49, 58) . Therefore, we asked whether activation of PPAR␥ in AGS cells by its specific agonist, TGN, affected PMA-induced IL-8 levels, and, if so, what was the role of MUC1 in this response. Our prior study demonstrated that TGN dose-dependently increased PPAR␥ binding to an oligonucleotide corresponding to the putative PPAR␥ binding site in the Muc1 gene promoter, thereby validating the ability of TGN to block PPAR␥ binding activity (42) . AGS cells pretreated with 1.0 M TGN prior to PMA treatment had reduced levels of IL-8 in culture media compared with cells treated with PMA alone (Fig. 2A) . In contrast, IL-8 levels were equal in AGS cells transfected with the MUC1 siRNA and treated with PMA plus TGN or with PMA alone, by both ELISA (Fig. 2B) and Western blot analysis (Fig. 2C) . Similarly, MUC1-expressing AGS cells treated with TGN and PMA also had reduced levels of IL-8 gene transcription, as assessed using an IL-8 gene promoterluciferase reporter, compared with cells treated with PMA alone, while IL-8 transcription was equal in AGS cells transfected with the MUC1 siRNA and treated with TGN plus PMA or with PMA alone (Fig. 2D) . The viability of the cells was unaffected by treatment with PMA or PMA plus TGN (Fig.  2E) . In summary, these results suggest that PPAR␥ suppresses PMA-stimulated IL-8 production through MUC1.
TGN inhibits H. pylori-stimulated IL-8 production. Because our prior report showed that knockdown of MUC1 expression reduced IL-8 levels in AGS cell culture medium following H. pylori treatment (35) , and because PMA stimulates IL-8 production through a TLR-independent, NK-B-dependent pathway (4), and we next sought to determine the roles of MUC1 and PPAR␥ in H. pylori-stimulated IL-8 production. We first verified that Muc1 gene knockout (Muc1 Ϫ/Ϫ ) mice exhibited increased inflammatory cell infiltration into the gastric mucosa compared with wild-type littermates by using an in vivo model of H. pylori infection that routinely produces Ͼ 90% gastric colonization with a cellular infiltrate consisting of Ͼ 80% neutrophils and the remainder of the cells (Ͻ 20%) comprising macrophages, plasma cells, eosinophils, and lymphocytes (13, 14). Significantly greater neutrophil infiltrations of the gastric mucosa and submucosa were seen in H. pylori-infected Muc1 Ϫ/Ϫ mice compared with infected Muc1 ϩ/ϩ mice (Fig. 3 ), and this difference was seen both in the corpus and antrum. Next, the effects of TGN on in vitro H. pylori-stimulated IL-8 production in the context of MUC1 expression were determined in human AGS and NCI-N87 gastric epithelial cells. Compared with AGS cells, NCI-N87 cells possess a more differentiated epithelial phenotype, forming a polarized monolayer in vitro with prominent intercellular junctions expressing zonula occludens and zonula adherens proteins, maintenance of transepithelial electrical resistance for up to 2 wk postconfluence, and high levels of IL-8 production in response to H. pylori (5, 19, 31) . Treatment of AGS (Fig. 4A ) and NCI-N87 (Fig. 4B) (Fig. 4, bars b vs. bars a) . Furthermore, transfection of the cells with the MUC1 siRNA prior to H. pylori treatment increased IL-8 levels, compared with bacteria-treated cells transfected with the nontargeting control siRNA (bars c vs. bars a). Unlike MUC1-expressing cells, however, the levels of IL-8 in culture media of MUC1 siRNA-transfected cells treated with H. pylori plus TGN were equal to those in the media of MUC1 siRNA-transfected cells treated with H. pylori alone (bars d vs. bars c). Taken together, these results suggest that, similar to its effects on PMA, PPAR␥ suppresses H. pyloriinduced IL-8 production through a MUC1-dependent mechanism.
TGN stimulates Muc1 promoter activity and increases protein levels. The mouse Muc1 gene promoter contains a putative PPAR␥ response element, and PPAR␥ was reported to increase MUC1 mRNA levels in mouse trophoblast stem cells (48) . Analysis of the 1,051 nucleotide proximal promoter of the human Muc1 gene identified a reverse sequence (5=-TCACCT-GTCACCT-3=) 73 bp upstream of the transcription start site corresponding to a possible PPAR␥ binding site, as well as binding sites for other transcription factors (1, 27, 48) (Fig. 5) . This putative PPAR␥ binding sequence in the human Muc1 promoter is 92.3% identical to the known mouse Muc1 PPAR␥ binding element (5=-TTACCTGTCACCT-3=, identical residues are underlined) and 84.6% identical to the PPAR binding consensus sequence (48) . We first verified that TGN treatment of AGS cells increased binding of PPAR␥ to the Muc1 gene promoter by chromatin immunoprecipitation. Two-fold greater immunoprecipitation of PPAR␥ to a 320 bp amplicon containing this putative PPAR␥ binding element was seen following treatment of AGS cells with 1.0 M TGN compared with the vehicle control (Fig. 6) . To determine whether PPAR␥ regulates human Muc1 gene expression, AGS cells were transiently transfected with a Muc1 gene promoter-luciferase reporter gene (Muc1-pGL2b) or the empty pGL2b vector as a negative control, incubated for 24 h with 0.1 or 1.0 M TGN, or DMSO vehicle control, and relative luciferase activity was measured. TGN treatment dose-dependently increased luciferase activity in the Muc1-pGL2b-transfected cells, but not in pGL2b-transfected cells, compared with the DMSO control (Fig. 7A) . Both concentrations of TGN also increased MUC1 protein levels in AGS cells (Fig. 7B) . To correlate the effects of TGN treatment on PMA-and H. pylori-stimulated IL-8 production in MUC1 siRNA-transfected cells (Figs. 2B and 3) , Western blot analysis revealed that the increased level of MUC1 produced by 1.0 M 
A: Muc1
ϩ/ϩ and Muc1 Ϫ/Ϫ mice were challenged with H. pylori SS1, and the gastric mucosa was assessed at 4 wk postinfection for neutrophil numbers. Tissue sections were Giemsa stained and the numbers of neutrophils were quantified in a blinded fashion as described (14) . Each group contained 4 to 6 mice. B: representative gastric histopathology in Muc1 ϩ/ϩ (i, ii) and Muc1
Ϫ/Ϫ (iii, iv) mice following inoculation with PBS vehicle control (i, iii) or H. pylori infection (ii, iv)
at 4 wk postinfection. Arrows indicate inflammatory cell infiltrates. Original magnification was ϫ100 or ϫ200 (insets).
TGN also was completely inhibited in MUC1 siRNA-transfected cells (Fig. 7C) . Finally, based on our previous study demonstrating that TNF-␣ increased MUC1 expression in airway epithelial cells (10, 25) , cotreatment of gastric AGS cells with TNF-␣ plus TGN increased MUC1 protein levels compared with cells treated with TNF-␣ or TGN alone (Fig.  7D ). In conclusion, these collective results suggest that PPAR␥ stimulates MUC1 transcription and associated protein levels, likely through binding to a putative PPAR␥ response element in its proximal gene promoter. We considered several possible PPAR␥-independent mechanisms to account for the increased MUC1 expression following treatment of cells with TGN. First, cross-stimulation of PPAR␣ and/or PPAR␤ by TGN does not appear likely because neither receptor is expressed by gastric epithelium (2). Second, TGN contains an ␣-tocopheroyl moiety, potentially giving it antioxidant activity (40) . However, this alternative mechanism of action also appears unlikely based on a prior study demonstrating decreased MUC1 expression following treatment of epithelial cells with antioxidants (29) . Finally, phosphorylation of ERK1/2 through the TNF-␣ receptor is known to activate MUC1 expression (25, 29) , and Bolden et al. (8) recently demonstrated that treatment of human prostate cancer cells with TGN induced ERK1/2 phosphorylation via a PPAR␥-independent pathway. However, this effect was only observed at relatively high TGN concentrations (40 M) and no effect on ERK1/2 activation was seen at the doses used in the present study (Ͻ 1.0 M). A preceding report also demonstrated that MUC1 expression was lost in PPAR␥ knockout mice, and that mice heterozygous for PPAR␥ expressed intermediate levels of MUC1 compared with homozygous littermates, suggesting that MUC1 expression is directly proportional to the amount of PPAR␥ (48) . Additionally, given our previously published studies demonstrating that MUC1 suppresses proinflammatory responses stimulated by multiple TLRs (TLR2, 3, 4, 5, 7, and 9) (35, 53), we hypothesize that the MUC1 knockdown effect is much more effective in the presence of H. pylori vs. PMA given that the former expresses a variety of diverse TLR agonists (lipopolysaccharide, heatshock protein 60, lipoproteins, CpG DNA, RNA) that can act additively in overall IL-8 production (45) .
The results of the present study are consistent with those of our prior publications in lung epithelial cells that documented the relationships between MUC1, TNF-␣, and PPAR␥ (10, 25, 45) . Initially, we reported that MUC1 expression in mouse lungs was relatively low under basal conditions, but rapidly increased following P. aeruginosa infection as a result of transcriptional activation through a TNF-␣-dependent pathway (10, 25) . At later stages of infection, increased MUC1 expression attenuated TNF-␣ levels to preinfection levels. Subsequently, we showed that treatment of A549 alveolar epithelial cells or primary mouse tracheal surface epithelial cells with PMA increased the levels of TNF-␣ in cell culture media compared with cells treated with vehicle alone (45) . Overexpression of MUC1 in A549 cells decreased PMA-stimulated TNF-␣ levels, whereas deficiency of Muc1 expression in MTSE cells from Muc1 null mice increased PMA-induced TNF-␣ levels. Treatment of A549 or MTSE cells with the TGN blocked the ability of PMA to stimulate TNF-␣ levels. However, the effect of TGN required the presence of MUC1, since no differences in TNF-␣ levels were seen between PMA and PMA plus TGN in MUC1-deficient cells. Further, electrophoretic mobility shift assay confirmed the presence of a PPAR␥ binding element in the Muc1 gene promoter of A549 cells. On the basis of these studies, combined with the present results demonstrating that cotreatment of AGS cells with TGN plus TNF-␣ increased MUC1 protein levels beyond that seen in cells treated with TNF-␣ or TGN alone, we speculate that the collective effects of increased PPAR␥ and TNF-␣ early following H. pylori exposure upregulates MUC1 expression that, in turn, dampens IL-8/KC production and reduces neutrophil infiltration in the gastric mucosa.
While the level of H. pylori infection of AGS cells (MOI ϭ 100) may seem comparatively high with potential cytotoxic effects on the gastric epithelial cells, other reports have documented bacteria-driven IL-8 production in the absence of overt toxicity using this same cell line and similar levels of infectivity (46, 59) . For example, the study by Ritter et al. (46) showed that in vitro IL-8 production by AGS cells at MOI ϭ 100 occurred by both CagA-dependent and CagA-independent pathways, thus mimicking the situation encountered in human clinical infections. In this study, no cytotoxic effects were observed in AGS cells following treatment with H. pylori strain 26695 at MOI ϭ 100 for 24 h.
PPARs comprise a family of ligand-activated transcription factors that belong to the nuclear receptor superfamily (44) . Following engagement by endogenous or synthetic ligands, PPARs translocate to the nucleus where they undergo heterodimerization with retinoid X receptors by binding to peroxisome proliferator response elements in the promoter region of target genes. Both the PPAR and retinoid X receptor families contain 3 isoforms, PPAR␣, -␤, and -␥, and RXR␥, -␣, and -␤/␦. Endogenous ligands for the PPARs include free fatty acids and eicosanoids. Synthetic PPAR ligands include the thiazolidinediones, such as rosiglitazone, pioglitazone, and TGN. Originally, PPARs were identified as being essential for glucose metabolism, but have since been shown to regulate a variety of cellular processes, including differentiation, development, carcinogenesis, and inflammation (7, 11, 54) . In particular, synthetic PPAR␥ ligands suppress inflammation in vitro and in vivo (6, 56) , including the gastric inflammatory response to H. pylori (49) , as well as airway inflammation following infection with P. aeruginosa (43) .
Our previous studies showed that MUC1 plays an important anti-inflammatory role during gastric and airway infection by bacterial and viral pathogens (18, 32, 35) . Muc1 Ϫ/Ϫ mice experimentally infected in the stomach with H. pylori or in the lungs with P. aeruginosa or respiratory syncytial virus, had higher levels of TNF-␣ and KC (murine IL-8) and enhanced NF-B activation in the respective epithelia compared with Muc1 ϩ/ϩ littermates. These effects appeared to be mediated through the action of the MUC1 cytoplasmic domain and, more specifically, by one or more of the potential intracellular tyrosine phosphorylation sites, since anti-inflammatory activity was lost using an intracellular tyrosine deficient MUC1 mutant (24) . Similar studies by others confirmed that murine MUC1 also counterregulates inflammatory responses against Staphylococcus, Streptococcus, and Corynebacterium, although the responsible mechanism was not described (21). In the case of H. pylori, McGuckin and colleagues (34, 39) have convincingly demonstrated that MUC1 expression decreases bacterial colonization of the gastric mucosa and reduces stomach inflammation by ectodomain steric hindrance and by acting as a soluble decoy released from the cell surface. It is therefore likely that MUC1 downregulate gastric epithelial inflammatory responses through multiple, nonoverlapping mechanisms through its extracellular and intracellular domains.
From the results of the present investigation, we now speculate that decreased H. pylori-induced stomach inflammation involves PPAR␥-mediated upregulation of MUC1 expression, probably through transcriptional activation of the Muc1 gene promoter. Because bacterial cells possess diverse pathogenassociated molecular patterns that activate inflammatory responses via TLR ¡ NF-B pathways (47) , and because PMA induces proinflammatory cytokine production primarily through a PKC ¡ NF-B pathway (4), we further hypothesize that increased MUC1 expression by PPAR␥ attenuates inflammation at level of their common component, NF-B. During H. pylori infection, TLR2 and TLR5, but not TLR4, as well as an intact cytotoxin-associated gene pathogenicity island (cagPAI) encoding a type-IV secretion system for injecting the cagA A putative PPAR␥ binding site based on homology to the mouse PPAR␥ binding site (48) , as well as previously reported regulatory elements for NF-B, Sp1, STAT1/3, and GATA1 are underlined (1, 27) .
protein into host epithelial cells, are required for NF-B activation and IL-8 production (15, 37, 50) . MUC1 blocks NF-B-dependent signaling by binding to IKK␥, the regulatory subunit of the IB kinase complex, and may suppress H. pylori-dependent IL-8 production in this manner (18) . Other potential mechanisms for MUC1's anti-inflammatory effect also may occur, for example through blockade of nonshared steps in the TLR and PKC signaling pathways or by inhibiting the intracellular actions of H. pylori cagA. Moreover, a recent report demonstrated that treatment of human uterine epithelial cells with the PPAR␥ agonist rosiglitazone did not alter MUC1 expression (55) , contradicting the reported results using mouse cells (48) and those herein. The authors speculated that nonresponsiveness of the human cells was due to the presence in the Muc1 promoter of a 21-nucleotide insertion in a motif corresponding to the PPAR␥ responsive enhancer sequence in the mouse promoter. Further comparative studies in human and mouse cells are required to clarify these apparent discrepancies and to identify the precise molecular relationships between MUC1, PPAR␥, NF-B, TLRs, and/or PKC. Fig. 6 . TGN induces peroxisome proliferator-associated receptor-␥ (PPAR␥) recruitment to the Muc1 promoter. A: AGS cells were treated for 1 h at 37°C with DMSO vehicle control or 1.0 M TGN. Cells were treated with formaldehyde to cross-link DNA-protein complexes, cell lysates were sonicated to shear DNA, and the sheared DNA was immunoprecipitated with PPAR␥ antibody. After reversal of cross-linking, the target DNA was amplified by PCR using Muc1 specific primers, and amplicons were visualized on ethidium bromide-stained agarose gels. B: densitometric analysis of the chromatin immunoprecipitation (ChIP) results. Each bar represents the mean Ϯ SE value (n ϭ 2). 
